Key Differences Among ALK Inhibitors

EP: 1.The Evolution of ALK+ NSCLC Care

EP: 2.Lorlatinib in Focus: Survival, Brain Metastases, and Beyond

EP: 3.Choosing Wisely: Insights from an MAIC and eXalt3

EP: 4.Applying Trial Data to Real-World Practice in ALK+ NSCLC

Now Viewing

EP: 5.Key Differences Among ALK Inhibitors

EP: 6.Navigating ALK Inhibitor Toxicities

EP: 7.Lorlatinib’s Unique Challenges: Managing Cognitive and Metabolic AEs

EP: 8.Long-Term Success: Educating and Supporting Patients on ALK Inhibitors

EP: 9.Equitable Access to Molecular Testing and Treatment Prioritization

EP: 10.Next Steps: Post-Frontline Therapies and Resistance in ALK+ NSCLC

EP: 11.Education and Support After Progression ALK Inhibitors

EP: 12.Looking Ahead: The Next Frontier in ALK+ NSCLC Therapy

ALK Inhibitor Comparison and CNS Penetration

Key Themes:

• Overview of currently available ALK inhibitors in the metastatic setting
• Comparative analysis of efficacy and durability of response
• Differences in CNS penetration among ALK inhibitors

Notable Insights:

• Dr Lovly provided a comprehensive overview of available ALK inhibitors and their comparative efficacy

Dr Dietrich highlighted clinically relevant differences in CNS penetration and their influence on therapy selection